A Phase 3 interventional study of Setmelanotide 2 mg and Setmelanotide 2.5 mg in Bardet-Biedl Syndrome and POMC Deficiency, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 7 sites in 6 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A trial to compare the weekly and daily formulations of setmelanotide in participants with genetic defects in the melanocortin-4 receptor pathway.
This study is designed to compare the safety, pharmacokinetics, and efficacy of weekly and daily formulations of setmelanotide in participants with obesity associated with biallelic or heterozygous POMC (pro-opiomelanocortin), PCSK1 (proprotein convertase subtilisin/kexin Type 1), LEPR (leptin receptor) genetic variants, and participants with Bardet-Biedl Syndrome (BBS).
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received subcutaneous (SC) injection of 2 mg setmelanotide once daily (QD) for 1 week in the run-in period.
Drug: Setmelanotide 2 mg
Participants received SC injection of 2.5 mg setmelanotide QD for 1 week in the run-in period.
Drug: Setmelanotide 2.5 mg
Participants received SC injection of 3 mg setmelanotide QD for 1 week in the run-in period.
Drug: Setmelanotide 3 mg
Participants who received 2 mg setmelanotide QD in the run-in period, received SC injection of 20 mg setmelanotide once weekly (QW) and placebo matched to setmelanotide QD for 13 weeks in the DB period.
Drug: Setmelanotide 20 mg
Participants who received 2.5 mg setmelanotide QD in the run-in period, received SC injection of 25 mg setmelanotide QW and placebo matched to setmelanotide QD for 13 weeks in the DB period.
Drug: Setmelanotide 25 mg
Participants who received 3 mg setmelanotide QD in the run-in period, received SC injection of 3 mg setmelanotide QD and placebo matched to setmelanotide QW for 13 weeks in the DB period.
Drug: Setmelanotide 3 mg
Participants who received 3 mg setmelanotide QD in the run-in period, received SC injection of 30 mg setmelanotide QW and placebo matched to setmelanotide QD for 13 weeks in the DB period.
Drug: Setmelanotide 30 mg
Participants who received 2 mg setmelanotide QD in the run-in period and 20 mg setmelanotide QW in the DB period, received SC injection of 20 mg setmelanotide QW for 13 weeks in the OL period.
Drug: Setmelanotide 20 mg
Participants who received 2.5 mg setmelanotide QD in the run-in period and 25 mg setmelanotide QW in the DB period, received SC injection of 25 mg setmelanotide QW for 13 weeks in the OL period.
Drug: Setmelanotide 25 mg
Participants who received 3 setmelanotide QD in the run-in period and 3 mg setmelanotide QD or 30 mg setmelanotide QW in the DB period, received SC injection of 30 mg setmelanotide QW for 13 weeks in the OL period.
Drug: Setmelanotide 30 mg
Administered as SC injection
Administered as SC injection
Administered as SC injection
Administered as SC injection
Administered as SC injection
Administered as SC injection
Maximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period
Maximum drug concentration determined directly from individual concentration-time data.
Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose at Week -1
Cmax of Setmelanotide After QW Administration
Maximum drug concentration determined directly from individual concentration-time data. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).
Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours postdose at Week 14
Time to Maximum Plasma Concentration (Tmax) of Setmelanotide After QD Administration in the Run-in Period
Maximum drug concentration determined directly from individual concentration-time data.
Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose at Week -1
Tmax of Setmelanotide After QW Administration
Maximum drug concentration determined directly from individual concentration-time data. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).
Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours postdose at Week 14
Mean Trough Plasma Concentration (Ctrough) of Setmelanotide After QD or QW Administration at Week 1
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
Time frame: 30 minutes predose at Week 1
Mean Setmelanotide Ctrough After QD or QW Administration at Week 5
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
Time frame: 30 minutes predose at Week 5
Mean Setmelanotide Ctrough After QD or QW Administration at Week 9
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
Time frame: 30 minutes predose at Week 9
Mean Setmelanotide Ctrough After QD or QW Administration at Week 18
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
Time frame: 30 minutes predose at Week 18
Mean Setmelanotide Ctrough After QD or QW Administration at Week 22
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
Time frame: 30 minutes predose at Week 22
Mean Setmelanotide Ctrough After QD or QW Administration at Week 27
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
Time frame: 30 minutes predose at Week 27
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of Setmelanotide After QD Administration in the Run-in Period
AUC0-tau was recorded from collected blood samples.
Time frame: Pre-dose (0 hour) and at 0.5, 1, 2, 3, 4, 6, and 8 hours postdose at Week -1
AUC0-tau of Setmelanotide After QD Administration in the Run-in Period
AUC0-tau was recorded from collected blood samples. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).
Time frame: Pre-dose (0 hour) and 0.5, 1, 2, 6, 8, 12, 24, 48, 72, 96, 120, and 168-hours postdose at Week 14
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. The AEs reported after the start of the run-in period were considered TEAEs.
Time frame: From first dose of study drug administration up to Week 30
Number of Participants With Injection Site Reactions (ISRs) From Baseline Through Week 13
The injection site evaluation included the identification of areas of erythema, edema, and induration, as well as the presence of localized pain, tenderness, and itching. Baseline was defined as the last available measurement prior to the first dose of setmelanotide or placebo. Injection site reactions frequency of once daily (QD) and once weekly (QW) were reported. Data are reported by dose level (treatment regimen) in the DB Period. Number of participants with injection site reactions according to severity were reported.
Time frame: Baseline through Week 13
Number of Participants With ISRs From Week 14 Through Week 27
The injection site evaluation included the identification of areas of erythema, edema, and induration, as well as the presence of localized pain, tenderness, and itching. Injection site reactions frequency of QD and QW were reported. Data are reported by dose level (treatment regimen) in the OL Period. Number of participants with injection site reactions according to severity were reported.
Time frame: Week 14 through Week 27
| Milestone | Run-in Period: Setmelanotide 2 mg QD | Run-in Period: Setmelanotide 2.5 mg QD | Run-in Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 20 mg QW | DB Period: Setmelanotide 25 mg QW | DB Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 30 mg QW | OL Period: Setmelanotide 20 mg QW | OL Period: Setmelanotide 25 mg QW | OL Period: Setmelanotide 30 mg QW |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 1 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 1 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Run-in Period: Setmelanotide 2 mg QD | Run-in Period: Setmelanotide 2.5 mg QD | Run-in Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 20 mg QW | DB Period: Setmelanotide 25 mg QW | DB Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 30 mg QW | OL Period: Setmelanotide 20 mg QW | OL Period: Setmelanotide 25 mg QW | OL Period: Setmelanotide 30 mg QW |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 2 | 1 | 9 | 7 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 1 | 1 | 7 | 7 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Run-in Period: Setmelanotide 2 mg QD | Run-in Period: Setmelanotide 2.5 mg QD | Run-in Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 20 mg QW | DB Period: Setmelanotide 25 mg QW | DB Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 30 mg QW | OL Period: Setmelanotide 20 mg QW | OL Period: Setmelanotide 25 mg QW | OL Period: Setmelanotide 30 mg QW |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 14 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 13 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Maximum drug concentration determined directly from individual concentration-time data.
| nanograms per milliliter (ng/mL) | Setmelanotide 2 mg QD | Setmelanotide 2.5 mg QD | Setmelanotide 3 mg QD |
|---|---|---|---|
| Maximum Drug Concentration (Cmax) of Setmelanotide After QD Administration in the Run-in Period | 29.4 ± 3.49 | 44.8 | 59.9 ± 29.6 |
Maximum drug concentration determined directly from individual concentration-time data. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).
| ng/mL | Setmelanotide 20 mg QW (QD-QW-QW) | Setmelanotide 25 mg QW (QD-QW-QW) | Setmelanotide 30 mg QW (QD-QD-QW) | Setmelanotide 30 mg QW (QD-QW-QW) |
|---|---|---|---|---|
| Cmax of Setmelanotide After QW Administration | 22.4 | 32.7 | 31.8 ± 28.6 | 57.3 ± 33.0 |
Maximum drug concentration determined directly from individual concentration-time data.
| hours | Setmelanotide 2 mg QD | Setmelanotide 2.5 mg QD | Setmelanotide 3 mg QD |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Setmelanotide After QD Administration in the Run-in Period | 6.91 (5.92 to 7.90) | 5.88 | 6.02 (2.00 to 8.00) |
Maximum drug concentration determined directly from individual concentration-time data. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).
| hours | Setmelanotide 20 mg QW (QD-QW-QW) | Setmelanotide 25 mg QW (QD-QW-QW) | Setmelanotide 30 mg QW (QD-QD-QW) | Setmelanotide 30 mg QW (QD-QW-QW) |
|---|---|---|---|---|
| Tmax of Setmelanotide After QW Administration | 3.93 | 5.93 | 1.98 (0.500 to 6.00) | 5.95 (2.03 to 6.03) |
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
| ng/mL | Setmelanotide 20 mg QW (QD-QW-QW) | Setmelanotide 25 mg QW (QD-QW-QW) | Setmelanotide 3 mg QD (QD-QD-QW) | Setmelanotide 30 mg QW (QD-QW-QW) |
|---|---|---|---|---|
| Mean Trough Plasma Concentration (Ctrough) of Setmelanotide After QD or QW Administration at Week 1 | 5.17 ± 0.856 | 4.36 | 11.7 ± 13.5 | 16.6 ± 16.3 |
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
| ng/mL | Setmelanotide 20 mg QW (QD-QW-QW) | Setmelanotide 25 mg QW (QD-QW-QW) | Setmelanotide 3 mg QD (QD-QD-QW) | Setmelanotide 30 mg QW (QD-QW-QW) |
|---|---|---|---|---|
| Mean Setmelanotide Ctrough After QD or QW Administration at Week 5 | — | 9.54 | 12.2 ± 7.62 | 15.6 ± 13.3 |
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
| ng/mL | Setmelanotide 20 mg QW (QD-QW-QW) | Setmelanotide 25 mg QW (QD-QW-QW) | Setmelanotide 3 mg QD (QD-QD-QW) | Setmelanotide 30 mg QW (QD-QW-QW) |
|---|---|---|---|---|
| Mean Setmelanotide Ctrough After QD or QW Administration at Week 9 | 11.1 | 6.43 | 12.3 ± 11.4 | 20.1 ± 13.7 |
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
| ng/mL | Setmelanotide 20 mg QW (QD-QW-QW) | Setmelanotide 25 mg QW (QD-QW-QW) | Setmelanotide 3 mg QD (QD-QD-QW) | Setmelanotide 30 mg QW (QD-QW-QW) |
|---|---|---|---|---|
| Mean Setmelanotide Ctrough After QD or QW Administration at Week 18 | 14.4 | 12.6 | 13.6 ± 13.9 | 26.2 ± 23.8 |
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
| ng/mL | Setmelanotide 20 mg QW (QD-QW-QW) | Setmelanotide 25 mg QW (QD-QW-QW) | Setmelanotide 3 mg QD (QD-QD-QW) | Setmelanotide 30 mg QW (QD-QW-QW) |
|---|---|---|---|---|
| Mean Setmelanotide Ctrough After QD or QW Administration at Week 22 | 11.9 | 14.3 | 17.0 ± 15.4 | 27.9 ± 25.4 |
Ctrough is concentration at the end of the dosing interval, prior to subsequent dose administration. Data are reported by dose level (treatment regimen) in the DB Period and dosing sequence (QD-QD-QW or QD-QW-QW).
| ng/mL | Setmelanotide 20 mg QW (QD-QW-QW) | Setmelanotide 25 mg QW (QD-QW-QW) | Setmelanotide 3 mg QD (QD-QD-QW) | Setmelanotide 30 mg QW (QD-QW-QW) |
|---|---|---|---|---|
| Mean Setmelanotide Ctrough After QD or QW Administration at Week 27 | 14.2 | 9.91 | 20.3 ± 19.4 | 32.1 ± 23.9 |
AUC0-tau was recorded from collected blood samples.
| hours*ng/mL | Setmelanotide 2 mg QD | Setmelanotide 2.5 mg QD | Setmelanotide 3 mg QD |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of Setmelanotide After QD Administration in the Run-in Period | — | — | 975 ± 659 |
AUC0-tau was recorded from collected blood samples. Data are reported by dose level (treatment regimen) in the OL Period and dosing sequence (QD-QD-QW or QD-QW-QW).
| hours*mg/mL | Setmelanotide 20 mg QW (QD-QW-QW) | Setmelanotide 25 mg QW (QD-QW-QW) | Setmelanotide 30 mg QW (QD-QD-QW) | Setmelanotide 30 mg QW (QD-QW-QW) |
|---|---|---|---|---|
| AUC0-tau of Setmelanotide After QD Administration in the Run-in Period | 1590 | 2260 | 2470 ± 2890 | 5010 ± 4000 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. The AEs reported after the start of the run-in period were considered TEAEs.
| Participants | Run-in Period: Setmelanotide 2 mg QD | Run-in Period: Setmelanotide 2.5 mg QD | Run-in Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 20 mg QW | DB Period: Setmelanotide 25 mg QW | DB Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 30 mg QW | OL Period: Setmelanotide 20 mg QW | OL Period: Setmelanotide 25 mg QW | OL Period: Setmelanotide 30 mg QW |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 0 | 0 | 1 | 2 | 1 | 9 | 6 | 0 | 1 | 10 |
The injection site evaluation included the identification of areas of erythema, edema, and induration, as well as the presence of localized pain, tenderness, and itching. Baseline was defined as the last available measurement prior to the first dose of setmelanotide or placebo. Injection site reactions frequency of once daily (QD) and once weekly (QW) were reported. Data are reported by dose level (treatment regimen) in the DB Period. Number of participants with injection site reactions according to severity were reported.
| Participants | Setmelanotide 20 mg QW | Setmelanotide 25 mg QW | Setmelanotide 3 mg QD | Setmelanotide 30 mg QW |
|---|---|---|---|---|
| Erythema QD — None | 2 | 0 | 7 | 5 |
| Erythema QD — Mild | 0 | 1 | 2 | 2 |
| Erythema QD — Moderate | 0 | 0 | 0 | 0 |
| Erythema QD — Severe | 0 | 0 | 0 | 0 |
| Erythema QW — None | 1 | 0 | 4 | 3 |
| Erythema QW — Mild | 1 | 1 | 4 | 3 |
| Erythema QW — Moderate | 0 | 0 | 1 | 1 |
| Erythema QW — Severe | 0 | 0 | 0 | 0 |
| Edema QD — None | 2 | 1 | 9 | 7 |
| Edema QD — Mild | 0 | 0 | 0 | 0 |
| Edema QD — Moderate | 0 | 0 | 0 | 0 |
| Edema QD — Severe | 0 | 0 | 0 | 0 |
| Edema QW — None | 2 | 1 | 9 | 6 |
| Edema QW — Mild | 0 | 0 | 0 | 1 |
| Edema QW — Moderate | 0 | 0 | 0 | 0 |
| Edema QW — Severe | 0 | 0 | 0 | 0 |
| Induration QD — None | 1 | 1 | 9 | 6 |
| Induration QD — Mild | 1 | 0 | 0 | 0 |
| Induration QD — Moderate | 0 | 0 | 0 | 1 |
| Induration QD — Severe | 0 | 0 | 0 | 0 |
| Induration QW — None | 1 | 0 | 8 | 4 |
| Induration QW — Mild | 1 | 1 | 1 | 2 |
| Induration QW — Moderate | 0 | 0 | 0 | 1 |
| Induration QW — Severe | 0 | 0 | 0 | 0 |
| Itching QD — None | 2 | 1 | 8 | 3 |
| Itching QD — Mild | 0 | 0 | 1 | 4 |
| Itching QD — Moderate | 0 | 0 | 0 | 0 |
| Itching QD — Severe | 0 | 0 | 0 | 0 |
| Itching QW — None | 2 | 1 | 9 | 2 |
| Itching QW — Mild | 0 | 0 | 0 | 4 |
| Itching QW — Moderate | 0 | 0 | 0 | 1 |
| Itching QW — Severe | 0 | 0 | 0 | 0 |
| Pain or Tenderness QD — None | 2 | 0 | 6 | 5 |
| Pain or Tenderness QD — Mild | 0 | 1 | 3 | 2 |
| Pain or Tenderness QD — Moderate | 0 | 0 | 0 | 0 |
| Pain or Tenderness QD — Severe | 0 | 0 | 0 | 0 |
| Pain or Tenderness QW — None | 2 | 0 | 6 | 1 |
| Pain or Tenderness QW — Mild | 0 | 1 | 3 | 2 |
| Pain or Tenderness QW — Moderate | 0 | 0 | 0 | 4 |
| Pain or Tenderness QW — Severe | 0 | 0 | 0 | 0 |
| Other QD — None | 1 | 1 | 9 | 7 |
| Other QD — Mild | 1 | 0 | 0 | 0 |
| Other QD — Moderate | 0 | 0 | 0 | 0 |
| Other QD — Severe | 0 | 0 | 0 | 0 |
| Other QW — None | 0 | 1 | 6 | 5 |
| Other QW — Mild | 2 | 0 | 3 | 1 |
| Other QW — Moderate | 0 | 0 | 0 | 1 |
| Other QW — Severe | 0 | 0 | 0 | 0 |
The injection site evaluation included the identification of areas of erythema, edema, and induration, as well as the presence of localized pain, tenderness, and itching. Injection site reactions frequency of QD and QW were reported. Data are reported by dose level (treatment regimen) in the OL Period. Number of participants with injection site reactions according to severity were reported.
| Participants | Setmelanotide 20 mg QW | Setmelanotide 25 mg QW | Setmelanotide 30 mg QW |
|---|---|---|---|
| Erythema QD — None | 1 | 1 | 13 |
| Erythema QD — Mild | 0 | 0 | 1 |
| Erythema QD — Moderate | 0 | 0 | 0 |
| Erythema QD — Severe | 0 | 0 | 0 |
| Erythema QW — None | 1 | 0 | 12 |
| Erythema QW — Mild | 0 | 1 | 2 |
| Erythema QW — Moderate | 0 | 0 | 0 |
| Erythema QW — Severe | 0 | 0 | 0 |
| Edema QD — None | 1 | 1 | 13 |
| Edema QD — Mild | 0 | 0 | 1 |
| Edema QD — Moderate | 0 | 0 | 0 |
| Edema QD — Severe | 0 | 0 | 0 |
| Edema QW — None | 1 | 1 | 14 |
| Edema QW — Mild | 0 | 0 | 0 |
| Edema QW — Moderate | 0 | 0 | 0 |
| Edema QW — Severe | 0 | 0 | 0 |
| Induration QD — None | 1 | 1 | 13 |
| Induration QD — Mild | 0 | 0 | 1 |
| Induration QD — Moderate | 0 | 0 | 0 |
| Induration QD — Severe | 0 | 0 | 0 |
| Induration QW — None | 0 | 0 | 8 |
| Induration QW — Mild | 1 | 1 | 4 |
| Induration QW — Moderate | 0 | 0 | 2 |
| Induration QW — Severe | 0 | 0 | 0 |
| Itching QD — None | 1 | 1 | 14 |
| Itching QD — Mild | 0 | 0 | 0 |
| Itching QD — Moderate | 0 | 0 | 0 |
| Itching QD — Severe | 0 | 0 | 0 |
| Itching QW — None | 1 | 1 | 10 |
| Itching QW — Mild | 0 | 0 | 4 |
| Itching QW — Moderate | 0 | 0 | 0 |
| Itching QW — Severe | 0 | 0 | 0 |
| Pain or Tenderness QD — None | 1 | 1 | 13 |
| Pain or Tenderness QD — Mild | 0 | 0 | 1 |
| Pain or Tenderness QD — Moderate | 0 | 0 | 0 |
| Pain or Tenderness QD — Severe | 0 | 0 | 0 |
| Pain or Tenderness QW — None | 1 | 1 | 8 |
| Pain or Tenderness QW — Mild | 0 | 0 | 6 |
| Pain or Tenderness QW — Moderate | 0 | 0 | 0 |
| Pain or Tenderness QW — Severe | 0 | 0 | 0 |
Collected over From first dose of study drug administration up to week 30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-in Period: Setmelanotide 2 mg QD | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Run-in Period: Setmelanotide 2.5 mg QD | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Run-in Period: Setmelanotide 3 mg QD | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| DB Period: Setmelanotide 20 mg QW | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| DB Period: Setmelanotide 25 mg QW | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| DB Period: Setmelanotide 3 mg QD | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| DB Period: Setmelanotide 30 mg QW | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| OL Period: Setmelanotide 20 mg QW | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| OL Period: Setmelanotide 25 mg QW | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| OL Period: Setmelanotide 30 mg QW | 0/14 (0%) | 0/14 (0%) | 10/14 (71.4%) |
| Event | Run-in Period: Setmelanotide 2 mg QD | Run-in Period: Setmelanotide 2.5 mg QD | Run-in Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 20 mg QW | DB Period: Setmelanotide 25 mg QW | DB Period: Setmelanotide 3 mg QD | DB Period: Setmelanotide 30 mg QW | OL Period: Setmelanotide 20 mg QW | OL Period: Setmelanotide 25 mg QW | OL Period: Setmelanotide 30 mg QW |
|---|---|---|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 0/2 | 0/1 | 1/16 | 1/2 | 1/1 | 4/9 | 2/7 | 0/1 | 1/1 | 0/14 |
| Injection site painGeneral disorders | 0/2 | 0/1 | 0/16 | 0/2 | 1/1 | 4/9 | 5/7 | 0/1 | 1/1 | 1/14 |
| Injection site indurationGeneral disorders | 0/2 | 0/1 | 0/16 | 1/2 | 1/1 | 2/9 | 2/7 | 0/1 | 1/1 | 1/14 |
| NasopharyngitisInfections and infestations | 0/2 | 0/1 | 0/16 | 0/2 | 1/1 | 1/9 | 1/7 | 0/1 | 1/1 | 2/14 |
| NauseaGastrointestinal disorders | 0/2 | 0/1 | 0/16 | 0/2 | 1/1 | 3/9 | 0/7 | 0/1 | 1/1 | 0/14 |
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 0/2 | 0/1 | 0/16 | 0/2 | 1/1 | 2/9 | 0/7 | 0/1 | 1/1 | 1/14 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/2 | 0/1 | 0/16 | 0/2 | 0/1 | 0/9 | 0/7 | 0/1 | 1/1 | 0/14 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/2 | 0/1 | 0/16 | 0/2 | 0/1 | 0/9 | 0/7 | 0/1 | 1/1 | 0/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/2 | 0/1 | 0/16 | 0/2 | 1/1 | 0/9 | 0/7 | 0/1 | 0/1 | 1/14 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/2 | 0/1 | 0/16 | 0/2 | 1/1 | 0/9 | 1/7 | 0/1 | 0/1 | 1/14 |
Full Analysis Set (FAS) included all participants who received at least 1 dose of setmelanotide after the randomization.
| Age, Continuous(years) | Setmelanotide 2 mg QD | Setmelanotide 2.5 mg QD | Setmelanotide 3 mg QD | Total |
|---|---|---|---|---|
| Mean | 20.0 ± 12.73 | 19.0 | 20.8 ± 8.30 | 20.6 ± 8.16 |
| Sex: Female, Male(Participants) | Setmelanotide 2 mg QD | Setmelanotide 2.5 mg QD | Setmelanotide 3 mg QD | Total |
|---|---|---|---|---|
| Female | 0 | 1 | 10 | 11 |
| Male | 2 | 0 | 6 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Setmelanotide 2 mg QD | Setmelanotide 2.5 mg QD | Setmelanotide 3 mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 2 |
| Not Hispanic or Latino | 2 | 1 | 14 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Setmelanotide 2 mg QD | Setmelanotide 2.5 mg QD | Setmelanotide 3 mg QD | Total |
|---|---|---|---|---|
| Race — Asian | 1 | 0 | 0 | 1 |
| Race — White | 1 | 1 | 14 | 16 |
| Race — Other | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2021 to primary completion in Oct 2023, 21 months.
Results were first posted in Nov 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. →